Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea · Delayed Price · Currency is KRW 15,770
-80 (-0.50%)
Jun 10, 2026, 3:30 PM KST
Onconic Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 67,205 | 53,392 | 14,838 | 21,056 | 95 | 60 | |
Revenue Growth (YoY) | 196.21% | 259.82% | -29.53% | 22064.25% | 58.33% | - |
Cost of Revenue | 13.69 | 10.96 | 3.78 | 2.37 | 14,933 | 8,402 |
Gross Profit | 67,191 | 53,381 | 14,835 | 21,054 | -14,838 | -8,342 |
Selling, General & Admin | 39,408 | 30,370 | 8,087 | 2,463 | - | - |
Research & Development | 11,410 | 9,721 | 10,929 | 15,761 | - | - |
Amortization of Goodwill & Intangibles | 0.98 | 1.18 | 1.18 | 1.18 | - | - |
Other Operating Expenses | 200.77 | 142.77 | 164.15 | 138.3 | - | - |
Operating Expenses | 51,565 | 40,762 | 19,632 | 18,823 | - | - |
Operating Income | 15,627 | 12,619 | -4,798 | 2,231 | -14,838 | -8,342 |
Interest Expense | -9.41 | -11.68 | -664.16 | -1,776 | -1,078 | -6,831 |
Interest & Investment Income | 1,436 | 1,387 | 942.63 | 863.01 | 1,431 | 18.85 |
Currency Exchange Gain (Loss) | 1,218 | -282.81 | 2,020 | -79.65 | - | - |
Other Non Operating Income (Expenses) | 2.42 | 1.65 | -7,442 | -576.09 | 52.86 | 5.74 |
EBT Excluding Unusual Items | 18,274 | 13,713 | -9,942 | 662.51 | -14,432 | -15,149 |
Gain (Loss) on Sale of Investments | 10.77 | 10.77 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | -0.7 | - | - |
Pretax Income | 18,285 | 13,724 | -9,942 | 661.81 | -14,432 | -15,149 |
Income Tax Expense | -2,043 | -2,060 | -1,849 | -1,021 | - | - |
Net Income | 20,328 | 15,784 | -8,093 | 1,682 | -14,432 | -15,149 |
Net Income to Common | 20,328 | 15,784 | -8,093 | 1,682 | -14,432 | -15,149 |
Shares Outstanding (Basic) | - | 44 | 33 | 23 | 23 | 23 |
Shares Outstanding (Diluted) | - | 45 | 33 | 23 | 23 | 23 |
Shares Change (YoY) | - | 38.72% | 41.46% | -0.00% | 0.94% | - |
EPS (Basic) | - | 358.67 | -247.45 | 72.78 | -624.23 | -661.40 |
EPS (Diluted) | - | 347.92 | -247.45 | 72.78 | -624.23 | -661.40 |
Free Cash Flow | 13,245 | 11,092 | -7,982 | 2,983 | -17,536 | -8,861 |
Free Cash Flow Per Share | - | 244.50 | -244.07 | 129.01 | -758.49 | -386.90 |
Gross Margin | 99.98% | 99.98% | 99.98% | 99.99% | - | - |
Operating Margin | 23.25% | 23.64% | -32.33% | 10.60% | -15618.48% | -13903.24% |
Profit Margin | 30.25% | 29.56% | -54.54% | 7.99% | -15191.48% | -25247.72% |
Free Cash Flow Margin | 19.71% | 20.77% | -53.79% | 14.16% | -18458.96% | -14769.11% |
EBITDA | 16,174 | 13,148 | -4,345 | 2,691 | -14,770 | -8,292 |
EBITDA Margin | 24.07% | 24.63% | -29.28% | 12.78% | - | - |
D&A For EBITDA | 547.38 | 528.44 | 452.67 | 460.13 | 67.43 | 49.65 |
EBIT | 15,627 | 12,619 | -4,798 | 2,231 | -14,838 | -8,342 |
EBIT Margin | 23.25% | 23.64% | -32.33% | 10.60% | - | - |